Compare Bristol-Myers Squibb Co (BMY) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.49 (market cap $116.30B), while iShares 3 7 Year Treasury Bond ETF trades at $116.96. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares 3 7 Year Treasury Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | IEI | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $120.72 |
52-Week Low | $42.60 | $116.45 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.45, down 0.27% on the day. The technical outlook is bearish, with moving averages signaling a downtrend, though oscillators are neutral. Recent news highlights competition from Vanguard bond ETFs on yield and cost, while broader bond market inflows surge amid Fed policy uncertainty. The fund maintains regular dividend distributions, with recent payments around $0.36-$0.37 per share.
The outlook for IEI is cautious due to bearish technicals and competitive pressure from higher-yielding alternatives. Rising interest rate expectations pose a headwind, but its Treasury focus offers lower volatility. Key risks include Fed policy shifts and inflation persistence. Investors seeking intermediate-term government bond exposure may find stability, but yield hunters might prefer corporate or broader market ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
